Pharmaceutical Firm, Ipsen, Signs Long-Term Lease At Multi-Tenant Research Facility In Cambridge, Massachusetts
Area Development Online News Desk (09/27/2013)
BioMed Realty Trust, Inc. and Ipsen signed a long-term new lease for approximately 62,600 square feet of laboratory and office space in Cambridge, Massachusetts at 650 East Kendall Street, a six-story, state-of-the-art multi-tenant research facility in the heart of the Kendall Square biotechnology super-cluster.
Ipsen is a global specialty-driven pharmaceutical company whose focus is to develop specialty healthcare solutions for targeted debilitating diseases. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins.
The 650 East Kendall property is an approximately 282,200 square foot life science research facility that is supported by six levels of below-grade parking. The building, which BioMed Realty owns through a joint venture with Prudential Real Estate Investors on behalf of institutional investors, received Gold status certification by the Leadership in Energy and Environmental Design of the U.S. Green Building Council.
"We are very excited about expanding our research and development efforts to Cambridge, a leading hub in biotechnology research," according to Cynthia Sylvestre, President, Biomeasure and Vice President and Milford Site Head, Ipsen. "This move puts our research capabilities in the center of Kendall Square, one of the preeminent life science communities in the world, including prominent hospital centers, medical schools, biotech companies and universities. We are also excited about partnering with BioMed Realty with their specialized expertise in life science real estate."
Commenting on the new, long-term lease with Ipsen, Alan D. Gold, BioMed Realty's Chairman and Chief Executive Officer, said, "We are very excited that Ipsen has chosen 650 East Kendall as its Cambridge home for discovery and development of its programs. Ipsen's product offerings, pipeline and global partnership activity serve as a model of scientific innovation and achievement. We look forward to delivering the state-of-the-art facilities that will meet their requirements for years to come."